CTD格式介绍(中英文对照)
合集下载
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
2.3.P DRUG PRODUCT (NAME, DOSAGE FORM) ............................................................. 9
2.3.P.1 Description and Composition of the Drug Product (name, dosage form) ........9 2.3.P.2 Pharmaceutical Development (name, dosage form) .........................................9 2.3.P.3 Manufacture (name, dosage form).....................................................................9 2.3.P.4 Control of Excipients (name, dosage form) .....................................................10 2.3.P.5 Control of Drug Product (name, dosage form) ................................................10 2.3.P.6 Reference Standards or Materials (name, dosage form) ................................10 2.3.P.7 Container Closure System (name, dosage form) ............................................10 2.3.P.8 Stability (name, dosage form)..........................................................................10
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH
(name, dosage form, manufacturer) ................................................................12 2.3.A.3 Excipients .........................................................................................................12
(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002)
2002 年 9 月 11-12 日华盛顿会议一致通过采用统一编号和标题并在 e-CTD 中使用
2002 年 9 月 11-12 日华盛顿会议一致通过采用统一编号和标题并在 e-CTD 中使用
i
The Common Technical Document - QuaE 2 : COMMON TECHNICAL DOCUMENT SUMMARIES ................................ 6 2.3 : QUALITY OVERALL SUMMARY (QOS) ...................................................................... 6 INTRODUCTION......................................................................................................................... 6 2.3.S DRUG SUBSTANCE (NAME, MANUFACTURER) .................................................... 6
3.1. TABLE OF CONTENTS OF MODULE 3 ........................................................................ 13 3.2. BODY OF DATA ................................................................................................................. 13 3.2.S DRUG SUBSTANCE (NAME, MANUFACTURER) .................................................. 13
2.3.S.1 General Information (name, manufacturer) .....................................................6 2.3.S.2 Manufacture (name, manufacturer)..................................................................7 2.3.S.3 Characterisation (name, manufacturer) ...........................................................7 2.3.S.4 Control of Drug Substance (name, manufacturer) ...........................................8 2.3.S.5 Reference Standards or Materials (name, manufacturer) ...............................8 2.3.S.6 Container Closure System (name, manufacturer)............................................9 2.3.S.7 Stability (name, manufacturer) .........................................................................9
2.3.R REGIONAL INFORMATION ....................................................................................... 12
MODULE 3 : QUALITY ................................................................................................... 13
2.3.A APPENDICES .................................................................................................................. 12
2.3.A.1 Facilities and Equipment (name, manufacturer) ...........................................12 2.3.A.2 Adventitious Agents Safety Evaluation
THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE:
人用药物注册通用技术文件 QUALITY 质量
QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY 模块 2：质量概要 模块 3：质量
并按照 ICH 程序经法规部协商。进程第 4 步最终草案已被欧盟、日本和美国采纳
THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE:
人用药物注册通用技术文件 QUALITY 质量
QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY 模块 2：质量概要 模块 3：质量
ICH HARMONISED TRIPARTITE GUIDELINE ICH 三方协调指南
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 9 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH
(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002) ICH 指导委员会会议 ICH 进程第 4 步 2000 年 11 月 9 日 该指南建议三方法规处采用 ICH
Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA. 该指南已经合格的专家工作组研究
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 9 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH ICH 指导委员会会议 ICH 进程第 4 步 2000 年 11 月 9 日 该指南建议三方法规处采用 ICH
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 人用药物注册技术要求国际协调会议
ICH HARMONISED TRIPARTITE GUIDELINE ICH 三方协调指南
2.3.P.1 Description and Composition of the Drug Product (name, dosage form) ........9 2.3.P.2 Pharmaceutical Development (name, dosage form) .........................................9 2.3.P.3 Manufacture (name, dosage form).....................................................................9 2.3.P.4 Control of Excipients (name, dosage form) .....................................................10 2.3.P.5 Control of Drug Product (name, dosage form) ................................................10 2.3.P.6 Reference Standards or Materials (name, dosage form) ................................10 2.3.P.7 Container Closure System (name, dosage form) ............................................10 2.3.P.8 Stability (name, dosage form)..........................................................................10
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH
(name, dosage form, manufacturer) ................................................................12 2.3.A.3 Excipients .........................................................................................................12
(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002)
2002 年 9 月 11-12 日华盛顿会议一致通过采用统一编号和标题并在 e-CTD 中使用
2002 年 9 月 11-12 日华盛顿会议一致通过采用统一编号和标题并在 e-CTD 中使用
i
The Common Technical Document - QuaE 2 : COMMON TECHNICAL DOCUMENT SUMMARIES ................................ 6 2.3 : QUALITY OVERALL SUMMARY (QOS) ...................................................................... 6 INTRODUCTION......................................................................................................................... 6 2.3.S DRUG SUBSTANCE (NAME, MANUFACTURER) .................................................... 6
3.1. TABLE OF CONTENTS OF MODULE 3 ........................................................................ 13 3.2. BODY OF DATA ................................................................................................................. 13 3.2.S DRUG SUBSTANCE (NAME, MANUFACTURER) .................................................. 13
2.3.S.1 General Information (name, manufacturer) .....................................................6 2.3.S.2 Manufacture (name, manufacturer)..................................................................7 2.3.S.3 Characterisation (name, manufacturer) ...........................................................7 2.3.S.4 Control of Drug Substance (name, manufacturer) ...........................................8 2.3.S.5 Reference Standards or Materials (name, manufacturer) ...............................8 2.3.S.6 Container Closure System (name, manufacturer)............................................9 2.3.S.7 Stability (name, manufacturer) .........................................................................9
2.3.R REGIONAL INFORMATION ....................................................................................... 12
MODULE 3 : QUALITY ................................................................................................... 13
2.3.A APPENDICES .................................................................................................................. 12
2.3.A.1 Facilities and Equipment (name, manufacturer) ...........................................12 2.3.A.2 Adventitious Agents Safety Evaluation
THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE:
人用药物注册通用技术文件 QUALITY 质量
QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY 模块 2：质量概要 模块 3：质量
并按照 ICH 程序经法规部协商。进程第 4 步最终草案已被欧盟、日本和美国采纳
THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE:
人用药物注册通用技术文件 QUALITY 质量
QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY 模块 2：质量概要 模块 3：质量
ICH HARMONISED TRIPARTITE GUIDELINE ICH 三方协调指南
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 9 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH
(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002) ICH 指导委员会会议 ICH 进程第 4 步 2000 年 11 月 9 日 该指南建议三方法规处采用 ICH
Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA. 该指南已经合格的专家工作组研究
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 9 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH ICH 指导委员会会议 ICH 进程第 4 步 2000 年 11 月 9 日 该指南建议三方法规处采用 ICH
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 人用药物注册技术要求国际协调会议
ICH HARMONISED TRIPARTITE GUIDELINE ICH 三方协调指南